Fusion of a stabilized peptide tag to antibodies! Production of antibodies that function intracellularly (STAND).
Our company is engaged in collaborative drug discovery research using intracellular antibody STAND technology. Conventional antibodies are unstable and aggregate within cells, rendering them non-functional. The STAND technology is a versatile antibody stabilization technique that can approach disease treatment targets within cells without aggregation in the intracellular environment. Additionally, we also support the development of veterinary pharmaceuticals and research reagents. 【Business Overview】 ■ Drug discovery business using intracellular antibody STAND technology, collaborative drug development business, veterinary pharmaceutical development support, research reagent development support *For more details, please download the PDF or feel free to contact us.
Inquire About This Product
basic information
For more details, please download the PDF or feel free to contact us.
Price range
Delivery Time
Applications/Examples of results
For more details, please download the PDF or feel free to contact us.
catalog（1）
Download All Catalogs
Company information
Our company was established in November 2019 and is engaged in the development of innovative drugs utilizing stable intracellular antibodies (STAND). Unlike conventional antibodies that are unstable and aggregate within cells, STAND technology provides a versatile antibody that remains stable in the intracellular environment and can approach disease treatment targets. Through fundraising and technology development, we aim to realize innovative therapies for various diseases.
![[Research Material] Global Market for B Cell Maturation Antigen (BCMA) Targeted Therapy](https://image.mono.ipros.com/public/product/image/bc1/2001481377/IPROS33427504888589454849.jpeg?w=280&h=280)
![[Research Material] The Global Market for Prescription Drugs](https://image.mono.ipros.com/public/product/image/880/2001472266/IPROS88869514241408629549.jpeg?w=280&h=280)
